We are calling for research collaborators
On NGS-independent protocol for the cultivation of iPSC-derived functional cells/organoids
Background
GMExpression was founded with a focus on the expression of proteins and macromolecules. More recently, we have started expanding our capabilities to include the expression of functional mammalian cells and organoids, broadening our spectrum of both innovation and profession.
We are currently working on induced pluripotent stem cell (iPSC)-based therapies and related toolkits, which include specialised transfection vectors, self-assembling envelope agents, and customised culture media.
A lot of promising applications can be enabled by our toolkit and media, including:
- iPSC-derived organoid autologous transplants for diseases related to kidney islet failure.
- iPSC-derived tumour-infiltrating lymphocytes (TILs), serving as “rejuvenated” T cells for autologous cell-based cancer therapies.
Our findings are that the existing iPSC protocols present significant limitations. A major challenge is that iPSC-derived functional cell lines can readily undergo malignant transformation, which is difficult to detect at their early stage and eliminate in time, making iPSC-based pathways often labour- and time-intensive, as well as costly.
Currently, next-generation sequencing (NGS) is the primary method used to identify cancerous cells and abnormal oncogene expression or regulation. However, NGS is expensive, full-genome assessment is insufficiently precise even by AI, and requires NGS to be repeated, intensively applied throughout the entire iPSC-derived functional cell culture process.
Given that these directions represent highly promising applications worthy of long-term commitment and investment, we are willing to work and address this major challenge—not only for our own business, but also benefits peers in the field.
We aim to develop a novel NGS-independent protocol for the cultivation of iPSC-derived functional cells and organoids.
Our initial concept is to leverage iPSC-derived immune cells to identify and eliminate cancerous cells during the differentiation and culture of iPSC-derived functional cells.
The technological details can be disclosed and discussed when engaging in the collaboration.
We Are Seeking research collaborators
We invite scholars with expertise in immunology, oncology and stem cell differentiation who are interested in our direction mentioned above to become long-term collaborators.
Together, we can establish a cutting-edge research initiative and make a meaningful impact across both industrial and academic sectors.
What We Offer
-PhD Scholarship Funding: We are initially offering a PhD scholarship (UARS scholarship for collaborators at the University of Adelaide, and equivalent scholarships for other Australian universities) to support distinguished PhD candidates supervised by collaborators, and PhD candidates conducting research aligned with above mentioned direction.
-Grant Support: We commit to leveraging our resources, expertise, and technology reserves to help collaborators secure relevant grant applications, thereby building sustainable research capability with mutual benefit.
-CRC Development: Following initial achievements and successful first grant acquisition, we aim to establish a Cooperative Research Centre (CRC) on top of the ongoing research with the university to strengthen collaboration.
-Access to Established Scholars: We can introduce existing collaborators, including experts in autologous transplantation, renal medical research, and bioengineering, to form strong teams capable of winning strategically important grants.
-Long-term Research Funding: The company commits to using its own profits to support the collaborator’s research, provided that the research direction remains aligned with the company’s strategic interests.
Other benefits can be negotiated
We are open and flexible in building partnerships that advance this research direction.
Contact
Tocvic Meng
Director | Research and Development
E